Reporting from ADA 2024 - Atul Malhotra, MD: Tirzepatide for Obstructive Sleep Apnea and Obesity

With the results of the SURMOUNT-OSA trial demonstrating the benefit of tirzepatide (Zepbound) in obstructive sleep apnea (OSA) and obesity, the dual GIP/GLP-1 receptor agonist stands poised to usher in a new era of management for OSA.

“This study marks a significant milestone in the treatment of OSA, offering a promising new therapeutic option that addresses both respiratory and metabolic complications,” said Atul Malhotra, MD, lead author of the study, professor of medicine at University of California San Diego School of Medicine and director of sleep medicine at UC San Diego Health.

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

Source: MDMag